Indoco Pharmchem Limited

Indoco Pharmchem Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN U33112MH2012PLC232609 Incorporated 26 June 2012 ROC Mumbai HQ Mumbai, Maharashtra, India
Struck Off Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹1,845.32 Cr
▲ 10.84% YoY
EBITDA · FY 2026
₹145.13 Cr
▲ 38.6% YoY
Net profit · FY 2026
-₹98.7 Cr
▼ 26.62% YoY
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Open charges
None
Secured borrowings
Company age
14 yrs
Est. 2012
Last financials
Mar 2017
Balance sheet date

About Indoco Pharmchem Limited

Data last updated: 23 July 2025

Indoco Pharmchem Limited was a public limited company based in Mumbai, Maharashtra, India, operated as a subsidiary of Indoco Remedies Limited. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It specialised in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 June 2012.

Registered with ROC Mumbai under CIN U33112MH2012PLC232609.

Capital: an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It was led by directors including Sundeep Vasant Bambolkar and Aditi Milind Panandikar.

Last AGM: 08 August 2017. Financial statements filed for year ended 31 March 2017. Office: Indoco House 166 Cst Road Santacruz East, Mumbai, Maharashtra, India – 400098.

It operated as a subsidiary of Indoco Remedies Limited.

The company is no longer operational and has been struck off from the Register of Companies, typically due to non-filing of annual returns or failure to commence business. Entering into any agreement with a struck-off entity carries significant legal and financial risk. The last known website on record is indoco.com.

Company Details of Indoco Pharmchem Limited
CIN U33112MH2012PLC232609
Registration Number 232609
Incorporation Date 26 June 2012
ROC Mumbai
Listing Status Unlisted
Company Status Struck Off
Date of Last AGM 08 August 2017
Date of Balance Sheet 31 March 2017
Parent Company Indoco Remedies Limited
Key People
Sundeep Vasant Bambolkar Director Aditi Milind Panandikar Director Suresh Govind Kare Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    indoco.com
  • Social Media
  • Registered Address
    Indoco House 166 Cst Road Santacruz East, Mumbai, Maharashtra, India – 400098
  • Industry
    Pharma, Drug Formulation & Development
Company report
Indoco Pharmchem Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Indoco Pharmchem Limited report

Financials, compliance, directors, charges, ownership and filings for Indoco Pharmchem Limited in one report.

10-year financials Directors & ownership Charges & compliance

Auditor Details of Indoco Pharmchem Limited

Indoco Pharmchem Limited is audited by M/s. Gokhale & Sathe (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s. Gokhale & Sathe (ICAI peer reviewed, certificate valid till 2027-02-28) FY 2026 Declaration of unmodified opinion

Board of Directors of Indoco Pharmchem Limited

Indoco Pharmchem Limited is governed by 3 directors who oversee the company's operations and strategic decisions.

Directors (as last reported)
Name Designation Appointment Date Tenure Status
Sundeep Vasant Bambolkar
Also directs: Indoco Remedies Limited, Spa Holdings Private Limited, Warren Remedies Private Limited and 1 more
Director 26 Jun 2012 14 Years 0 Months As last reported
Aditi Milind Panandikar
Also directs: Indoco Remedies Limited, Warren Remedies Private Limited, Xtend Industrial Designers And Engineers Private Limited and 2 more
Director 26 Jun 2012 14 Years 0 Months As last reported
Suresh Govind Kare
Also directs: Indoco Remedies Limited, Spa Holdings Private Limited, Warren Remedies Private Limited and 2 more
Director 26 Jun 2012 14 Years 0 Months As last reported
View all directors

Financials of Indoco Pharmchem Limited FY 2026 filings available

Indoco Pharmchem Limited reported revenue of ₹1,845.32 Cr (up 10.84% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹1,845.32 Cr ▲ 10.84%
Profit · FY 2026
-₹98.7 Cr ▼ 26.62%
EBITDA · FY 2026
₹145.13 Cr ▲ 38.6%
Revenue₹ Cr · Consolidated01,0002,000FY 2020: ₹1,107 Cr1,107FY 2020FY 2021: ₹1,242 Cr · +12.2% YoY1,242+12.2%FY 2021FY 2022: ₹1,541 Cr · +24.1% YoY1,541+24.1%FY 2022FY 2023: ₹1,669 Cr · +8.3% YoY1,669+8.3%FY 2023FY 2024: ₹1,817 Cr · +8.9% YoY1,817+8.9%FY 2024FY 2025: ₹1,665 Cr · -8.4% YoY1,665-8.4%FY 2025FY 2026: ₹1,845 Cr · +10.8% YoY1,845+10.8%FY 2026
Net Profit₹ Cr · Consolidated-1000100200FY 2020: ₹24 Cr24.1FY 2020FY 2021: ₹93 Cr · +285.8% YoY93.1+285.8%FY 2021FY 2022: ₹155 Cr · +66.4% YoY155+66.4%FY 2022FY 2023: ₹142 Cr · -8.1% YoY142-8.1%FY 2023FY 2024: ₹97 Cr · -31.8% YoY97-31.8%FY 2024FY 2025: ₹78 Cr (loss) · -180.4% YoY-78FY 2025FY 2026: ₹99 Cr (loss) · -26.6% YoY-98.7FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0200400600Q1'25: ₹431 Cr · +1.2% YoY431+1.2%Q1'25Q2'25: ₹433 Cr · -10.2% YoY433-10.2%Q2'25Q3'25: ₹411 Cr · -10.6% YoY411-10.6%Q3'25Q4'25: ₹390 Cr · -13.2% YoY390-13.2%Q4'25Q1'26: ₹438 Cr · +1.5% YoY438+1.5%Q1'26Q2'26: ₹485 Cr · +12% YoY485+12%Q2'26Q3'26: ₹445 Cr · +8.5% YoY445+8.5%Q3'26Q4'26: ₹476 Cr · +21.9% YoY476+21.9%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,845.32 Cr ₹1,664.92 Cr ₹1,817.29 Cr ₹1,668.61 Cr ₹1,540.75 Cr ₹1,241.53 Cr ₹1,106.59 Cr
Other Income ₹3.33 Cr ₹5.45 Cr ₹9.85 Cr ₹2.34 Cr ₹2.33 Cr ₹3.12 Cr ₹2.44 Cr
Total Income ₹1,848.65 Cr ₹1,670.37 Cr ₹1,827.14 Cr ₹1,670.95 Cr ₹1,543.08 Cr ₹1,244.65 Cr ₹1,109.03 Cr
Cost of Materials Consumed ₹425.6 Cr ₹396.27 Cr ₹485.01 Cr ₹412.02 Cr ₹393.66 Cr ₹303.2 Cr ₹262.68 Cr
Purchases of Stock-in-Trade ₹143.55 Cr ₹140.93 Cr ₹115.66 Cr ₹102.72 Cr ₹89.43 Cr ₹63.04 Cr ₹75.8 Cr
Changes in Inventories -₹27.41 Cr -₹39.02 Cr -₹41.48 Cr ₹6.55 Cr -₹26.3 Cr -₹12.13 Cr -₹8.05 Cr
Employee Benefit Expense ₹425.69 Cr ₹394.05 Cr ₹361.93 Cr ₹322.58 Cr ₹293.7 Cr ₹274.02 Cr ₹256.51 Cr
Finance Costs ₹122.25 Cr ₹66.23 Cr ₹38.02 Cr ₹25.03 Cr ₹14.14 Cr ₹22.26 Cr ₹26.25 Cr
Depreciation & Amortisation ₹126.45 Cr ₹113.84 Cr ₹91.87 Cr ₹70.61 Cr ₹78.96 Cr ₹73.13 Cr ₹70.82 Cr
Other Expenses ₹736.09 Cr ₹673.43 Cr ₹651.86 Cr ₹538.64 Cr ₹462.92 Cr ₹389.13 Cr ₹396.44 Cr
Total Expenses ₹1,952.22 Cr ₹1,745.73 Cr ₹1,702.87 Cr ₹1,478.15 Cr ₹1,306.51 Cr ₹1,112.65 Cr ₹1,080.45 Cr
Profit Before Exceptional Items & Tax -₹103.57 Cr -₹75.36 Cr ₹124.27 Cr ₹192.8 Cr ₹236.57 Cr ₹132 Cr ₹28.58 Cr
Exceptional Items -₹2.94 Cr ₹99 Lakh ₹11.53 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹106.51 Cr -₹74.37 Cr ₹135.8 Cr ₹192.8 Cr ₹236.57 Cr ₹132 Cr ₹28.58 Cr
Total Tax Expense -₹7.81 Cr ₹3.58 Cr ₹38.79 Cr ₹50.55 Cr ₹81.77 Cr ₹38.95 Cr ₹4.46 Cr
Net Profit -₹98.7 Cr -₹77.95 Cr ₹97.01 Cr ₹142.25 Cr ₹154.8 Cr ₹93.05 Cr ₹24.12 Cr
  attributable to Owners -₹95.15 Cr -₹73.74 Cr ₹98.47 Cr ₹142.25 Cr ₹154.8 Cr ₹0 -
  attributable to NCI -₹3.55 Cr -₹4.21 Cr -₹1.46 Cr - - ₹0 -
Other Comprehensive Income ₹12.62 Cr -₹4.13 Cr ₹27 Lakh ₹1.44 Cr -₹5.33 Cr -₹86 Lakh -₹1.83 Cr
Total Comprehensive Income -₹86.08 Cr -₹82.08 Cr ₹97.28 Cr ₹143.69 Cr ₹149.47 Cr ₹92.19 Cr ₹22.29 Cr
EBITDA (computed) ₹145.13 Cr ₹104.71 Cr ₹254.16 Cr ₹288.44 Cr ₹329.67 Cr ₹227.39 Cr ₹125.65 Cr
Basic EPS ₹-10.70 ₹8.46 ₹10.53 ₹15.44 ₹16.80 ₹10.10 ₹2.62
Diluted EPS ₹-10.69 ₹8.45 ₹10.51 ₹15.42 ₹16.80 ₹10.10 ₹2.62
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,593.27 Cr ₹2,429.91 Cr ₹2,144.73 Cr ₹1,658.2 Cr
Non-current Assets ₹1,399.92 Cr ₹1,428.57 Cr ₹1,190.06 Cr ₹850.02 Cr
Current Assets ₹1,193.35 Cr ₹1,001.34 Cr ₹954.67 Cr ₹808.18 Cr
Property, Plant & Equipment ₹969.83 Cr ₹849.06 Cr ₹788.22 Cr ₹612.2 Cr
Inventories ₹405.21 Cr ₹419.35 Cr ₹353.06 Cr ₹325.99 Cr
Trade Receivables ₹489.17 Cr ₹352.41 Cr ₹406.2 Cr ₹350.94 Cr
Cash & Equivalents ₹25.93 Cr ₹12.1 Cr ₹14.86 Cr ₹10.93 Cr
Equity (Net Worth) ₹932.11 Cr ₹1,018.38 Cr ₹1,110.5 Cr ₹1,028.25 Cr
Equity Share Capital ₹18.46 Cr ₹18.45 Cr ₹18.44 Cr ₹18.43 Cr
Borrowings (Non-current) ₹516.02 Cr ₹542.56 Cr ₹364.14 Cr ₹158.54 Cr
Borrowings (Current) ₹519.83 Cr ₹451 Cr ₹307.82 Cr ₹174.31 Cr
Total Debt (computed) ₹1,035.85 Cr ₹993.56 Cr ₹671.96 Cr ₹332.85 Cr
Current Liabilities ₹1,052.55 Cr ₹807.99 Cr ₹612.33 Cr ₹424.51 Cr
Total Liabilities ₹1,661.16 Cr ₹1,411.53 Cr ₹1,034.23 Cr ₹629.95 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹192.23 Cr ₹94.93 Cr ₹156.7 Cr ₹178.83 Cr ₹173.83 Cr
Investing Cash Flow -₹101.61 Cr -₹339.11 Cr -₹433.83 Cr -₹208.18 Cr -₹121.41 Cr
Financing Cash Flow -₹76.8 Cr ₹241.42 Cr ₹280.44 Cr ₹22.81 Cr -₹44.37 Cr
Capital Expenditure ₹147.53 Cr ₹356.15 Cr ₹427.3 Cr ₹207.25 Cr ₹125.32 Cr
Free Cash Flow (computed) ₹44.7 Cr -₹261.22 Cr -₹270.6 Cr -₹28.42 Cr ₹48.51 Cr
Dividends Paid ₹1.91 Cr ₹13.9 Cr ₹20.71 Cr ₹20.72 Cr ₹13.79 Cr
Net Change in Cash ₹13.82 Cr -₹2.76 Cr ₹3.31 Cr -₹6.54 Cr ₹8.05 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹475.61 Cr ₹445.36 Cr ₹484.67 Cr ₹437.89 Cr ₹390.21 Cr ₹410.55 Cr ₹432.66 Cr ₹431.49 Cr ₹449.64 Cr ₹459.42 Cr ₹481.73 Cr ₹426.5 Cr
Other Income -₹4 Lakh ₹98 Lakh ₹76 Lakh ₹1.63 Cr ₹2.02 Cr ₹85 Lakh ₹1.56 Cr ₹1.03 Cr ₹2.66 Cr ₹2.35 Cr ₹4.43 Cr ₹41 Lakh
Total Income ₹475.57 Cr ₹446.34 Cr ₹485.43 Cr ₹439.52 Cr ₹392.23 Cr ₹411.4 Cr ₹434.22 Cr ₹432.52 Cr ₹452.3 Cr ₹461.77 Cr ₹486.16 Cr ₹426.91 Cr
Cost of Materials Consumed ₹109.18 Cr ₹97.89 Cr ₹112.99 Cr ₹105.53 Cr ₹85.86 Cr ₹109.91 Cr ₹94.26 Cr ₹106.24 Cr ₹121.8 Cr ₹129.3 Cr ₹130.94 Cr ₹102.97 Cr
Purchases of Stock-in-Trade ₹32.52 Cr ₹32.99 Cr ₹38.82 Cr ₹39.23 Cr ₹30.62 Cr ₹34.93 Cr ₹39.15 Cr ₹36.23 Cr ₹27.17 Cr ₹30.62 Cr ₹25.74 Cr ₹32.13 Cr
Changes in Inventories -₹69 Lakh -₹10.46 Cr -₹6.47 Cr -₹9.79 Cr -₹10.51 Cr -₹30.92 Cr ₹3.39 Cr -₹98 Lakh -₹8.09 Cr -₹17.6 Cr -₹9.37 Cr -₹6.42 Cr
Employee Benefit Expense ₹109.41 Cr ₹106.03 Cr ₹103.23 Cr ₹107.02 Cr ₹106.36 Cr ₹97.55 Cr ₹92.88 Cr ₹97.26 Cr ₹88.3 Cr ₹89.97 Cr ₹92.12 Cr ₹91.54 Cr
Finance Costs ₹45.92 Cr ₹25.64 Cr ₹24.56 Cr ₹26.12 Cr ₹17.98 Cr ₹16.11 Cr ₹17.83 Cr ₹14.31 Cr ₹12.05 Cr ₹10.07 Cr ₹8.11 Cr ₹7.79 Cr
Depreciation & Amortisation ₹32.49 Cr ₹32.01 Cr ₹32.25 Cr ₹29.7 Cr ₹28.78 Cr ₹28.72 Cr ₹28.82 Cr ₹27.52 Cr ₹26.23 Cr ₹24.35 Cr ₹21.41 Cr ₹19.88 Cr
Other Expenses ₹175.48 Cr ₹187.4 Cr ₹193.05 Cr ₹178.37 Cr ₹178.66 Cr ₹187.05 Cr ₹162.73 Cr ₹144.97 Cr ₹171.59 Cr ₹164.23 Cr ₹170.93 Cr ₹145.11 Cr
Total Expenses ₹504.31 Cr ₹471.5 Cr ₹498.43 Cr ₹476.18 Cr ₹437.75 Cr ₹443.35 Cr ₹439.06 Cr ₹425.55 Cr ₹439.05 Cr ₹430.94 Cr ₹439.88 Cr ₹393 Cr
Profit Before Exceptional Items & Tax -₹28.74 Cr -₹25.16 Cr -₹13 Cr -₹36.66 Cr -₹45.52 Cr -₹31.95 Cr -₹4.84 Cr ₹6.97 Cr ₹13.25 Cr ₹30.83 Cr ₹46.28 Cr ₹33.91 Cr
Exceptional Items ₹3.74 Cr -₹6.15 Cr -₹53 Lakh ₹0 ₹0 ₹99 Lakh ₹0 ₹0 ₹19.73 Cr -₹8.2 Cr ₹0 ₹0
Profit Before Tax -₹25 Cr -₹31.31 Cr -₹13.53 Cr -₹36.66 Cr -₹45.52 Cr -₹30.96 Cr -₹4.84 Cr ₹6.97 Cr ₹32.98 Cr ₹22.63 Cr ₹46.28 Cr ₹33.91 Cr
Total Tax Expense -₹1.32 Cr -₹1.86 Cr -₹4.32 Cr -₹31 Lakh -₹4.18 Cr -₹2.56 Cr ₹5.17 Cr ₹5.15 Cr ₹10.95 Cr ₹7.07 Cr ₹11.04 Cr ₹9.73 Cr
Net Profit -₹23.68 Cr -₹29.45 Cr -₹9.21 Cr -₹36.35 Cr -₹41.34 Cr -₹28.4 Cr -₹10.01 Cr ₹1.82 Cr ₹22.03 Cr ₹15.56 Cr ₹35.24 Cr ₹24.18 Cr
  attributable to Owners -₹21.64 Cr -₹29.79 Cr -₹7.93 Cr -₹35.79 Cr -₹40.39 Cr -₹26.39 Cr -₹9.57 Cr ₹2.62 Cr ₹22.7 Cr ₹16.3 Cr ₹35.08 Cr ₹24.39 Cr
  attributable to NCI -₹2.04 Cr ₹34 Lakh -₹1.28 Cr -₹56 Lakh -₹95 Lakh -₹2.01 Cr -₹44 Lakh -₹81 Lakh -₹67 Lakh -₹74 Lakh ₹16 Lakh -₹21 Lakh
Other Comprehensive Income ₹11.44 Cr -₹1.26 Cr ₹2.58 Cr -₹16 Lakh -₹2.93 Cr -₹13 Lakh -₹99 Lakh -₹8 Lakh ₹82 Lakh -₹11 Lakh -₹21 Lakh -₹23 Lakh
Total Comprehensive Income -₹12.24 Cr -₹30.71 Cr -₹6.63 Cr -₹36.51 Cr -₹44.27 Cr -₹28.53 Cr -₹11 Cr ₹1.74 Cr ₹22.85 Cr ₹15.45 Cr ₹35.03 Cr ₹23.95 Cr
EBITDA (computed) ₹49.67 Cr ₹32.49 Cr ₹43.81 Cr ₹19.16 Cr ₹1.24 Cr ₹12.88 Cr ₹41.81 Cr ₹48.8 Cr ₹51.53 Cr ₹65.25 Cr ₹75.8 Cr ₹61.58 Cr
Basic EPS ₹-2.57 ₹-3.20 ₹-1.00 ₹-3.94 ₹-4.48 ₹-3.08 ₹-1.09 ₹0.20 ₹2.39 ₹1.69 ₹3.82 ₹2.62
Diluted EPS ₹-2.56 ₹-3.19 ₹-1.00 ₹-3.94 ₹-4.48 ₹-3.08 ₹-1.08 ₹0.20 ₹2.39 ₹1.69 ₹3.82 ₹2.62
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,686.07 Cr ₹1,518.19 Cr ₹1,790.81 Cr ₹1,666.69 Cr ₹1,539.72 Cr ₹1,240.3 Cr ₹1,106 Cr
Other Income ₹29.64 Cr ₹18.48 Cr ₹8.51 Cr ₹2.33 Cr ₹2.32 Cr ₹3.12 Cr ₹2.43 Cr
Total Income ₹1,715.71 Cr ₹1,536.67 Cr ₹1,799.32 Cr ₹1,669.02 Cr ₹1,542.04 Cr ₹1,243.42 Cr ₹1,108.43 Cr
Cost of Materials Consumed ₹353.23 Cr ₹334.79 Cr ₹445.5 Cr ₹412.02 Cr ₹393.62 Cr ₹303.16 Cr ₹262.68 Cr
Purchases of Stock-in-Trade ₹140.12 Cr ₹140.93 Cr ₹115.66 Cr ₹102.72 Cr ₹89.43 Cr ₹63.04 Cr ₹75.8 Cr
Changes in Inventories ₹7.2 Cr -₹32.04 Cr -₹14.7 Cr ₹6.55 Cr -₹26.3 Cr -₹12.13 Cr -₹8.05 Cr
Employee Benefit Expense ₹393.63 Cr ₹368.74 Cr ₹350.55 Cr ₹321.15 Cr ₹292.41 Cr ₹272.88 Cr ₹255.32 Cr
Finance Costs ₹88.5 Cr ₹56.63 Cr ₹36.82 Cr ₹25.03 Cr ₹14.14 Cr ₹22.22 Cr ₹26.25 Cr
Depreciation & Amortisation ₹106.9 Cr ₹98.25 Cr ₹87.98 Cr ₹70.6 Cr ₹78.95 Cr ₹73.12 Cr ₹70.81 Cr
Other Expenses ₹634.74 Cr ₹577.73 Cr ₹635.82 Cr ₹539.36 Cr ₹463.56 Cr ₹389.78 Cr ₹396.91 Cr
Total Expenses ₹1,724.32 Cr ₹1,545.03 Cr ₹1,657.63 Cr ₹1,477.43 Cr ₹1,305.81 Cr ₹1,112.07 Cr ₹1,079.72 Cr
Profit Before Exceptional Items & Tax -₹8.61 Cr -₹8.36 Cr ₹141.69 Cr ₹191.59 Cr ₹236.23 Cr ₹131.35 Cr ₹28.71 Cr
Exceptional Items -₹2.86 Cr ₹99 Lakh ₹11.53 Cr ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹11.47 Cr -₹7.37 Cr ₹153.22 Cr ₹191.59 Cr ₹236.23 Cr ₹131.35 Cr ₹28.71 Cr
Total Tax Expense -₹5.81 Cr ₹1.36 Cr ₹36.58 Cr ₹50.23 Cr ₹81.71 Cr ₹38.96 Cr ₹4.46 Cr
Net Profit -₹5.66 Cr -₹8.73 Cr ₹116.64 Cr ₹141.36 Cr ₹154.52 Cr ₹92.39 Cr ₹24.25 Cr
Other Comprehensive Income ₹1.33 Cr -₹4.49 Cr ₹4 Lakh ₹1.44 Cr -₹5.33 Cr -₹86 Lakh -₹1.84 Cr
Total Comprehensive Income -₹4.33 Cr -₹13.22 Cr ₹116.68 Cr ₹142.8 Cr ₹149.19 Cr ₹91.53 Cr ₹22.41 Cr
EBITDA (computed) ₹186.79 Cr ₹146.52 Cr ₹266.49 Cr ₹287.22 Cr ₹329.32 Cr ₹226.69 Cr ₹125.77 Cr
Basic EPS ₹-0.61 ₹-0.95 ₹12.66 ₹15.34 ₹16.77 ₹10.03 ₹2.63
Diluted EPS ₹-0.61 ₹-0.95 ₹12.64 ₹15.32 ₹16.77 ₹10.03 ₹2.63
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,365.1 Cr ₹2,201.16 Cr ₹1,960.61 Cr ₹1,659.68 Cr
Non-current Assets ₹1,251.38 Cr ₹1,245.69 Cr ₹1,060.39 Cr ₹852.62 Cr
Current Assets ₹1,113.72 Cr ₹955.47 Cr ₹900.22 Cr ₹807.06 Cr
Property, Plant & Equipment ₹703.46 Cr ₹670.62 Cr ₹635.34 Cr ₹595.49 Cr
Inventories ₹321.83 Cr ₹362.87 Cr ₹310.42 Cr ₹325.99 Cr
Trade Receivables ₹541.2 Cr ₹374.05 Cr ₹408.02 Cr ₹350.82 Cr
Cash & Equivalents ₹12.94 Cr ₹7.06 Cr ₹7.47 Cr ₹9.99 Cr
Equity (Net Worth) ₹1,099.19 Cr ₹1,103.36 Cr ₹1,126.62 Cr ₹1,027.02 Cr
Equity Share Capital ₹18.46 Cr ₹18.45 Cr ₹18.44 Cr ₹18.43 Cr
Borrowings (Non-current) ₹301.61 Cr ₹346.25 Cr ₹216.01 Cr ₹158.54 Cr
Borrowings (Current) ₹403.99 Cr ₹407.27 Cr ₹297.65 Cr ₹174.32 Cr
Total Debt (computed) ₹705.6 Cr ₹753.52 Cr ₹513.66 Cr ₹332.86 Cr
Current Liabilities ₹875.47 Cr ₹695.01 Cr ₹562.25 Cr ₹427.25 Cr
Total Liabilities ₹1,265.91 Cr ₹1,097.8 Cr ₹833.99 Cr ₹632.66 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹226.35 Cr ₹90.77 Cr ₹176.78 Cr ₹175.59 Cr ₹173.55 Cr
Investing Cash Flow -₹87.38 Cr -₹259.79 Cr -₹301.69 Cr -₹205.31 Cr -₹121.41 Cr
Financing Cash Flow -₹133.09 Cr ₹168.62 Cr ₹122.39 Cr ₹22.81 Cr -₹44.37 Cr
Capital Expenditure ₹125.35 Cr ₹258.43 Cr ₹179.03 Cr ₹189.39 Cr ₹125.32 Cr
Free Cash Flow (computed) ₹101 Cr -₹167.66 Cr -₹2.25 Cr -₹13.8 Cr ₹48.23 Cr
Dividends Paid ₹1.91 Cr ₹13.9 Cr ₹20.71 Cr ₹20.72 Cr ₹13.79 Cr
Net Change in Cash ₹5.88 Cr -₹40 Lakh -₹2.52 Cr -₹6.91 Cr ₹7.77 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹449.13 Cr ₹400.51 Cr ₹442.12 Cr ₹392.53 Cr ₹347.25 Cr ₹372.98 Cr ₹396.53 Cr ₹401.43 Cr ₹445.49 Cr ₹449.05 Cr ₹473.39 Cr ₹422.88 Cr
Other Income ₹10.35 Cr ₹7.17 Cr ₹6.54 Cr ₹5.58 Cr ₹6.5 Cr ₹4.26 Cr ₹4.2 Cr ₹3.52 Cr ₹4.05 Cr ₹2.93 Cr ₹1.12 Cr ₹41 Lakh
Total Income ₹459.48 Cr ₹407.68 Cr ₹448.66 Cr ₹398.11 Cr ₹353.75 Cr ₹377.24 Cr ₹400.73 Cr ₹404.95 Cr ₹449.54 Cr ₹451.98 Cr ₹474.51 Cr ₹423.29 Cr
Cost of Materials Consumed ₹98.25 Cr ₹81.19 Cr ₹86.02 Cr ₹87.77 Cr ₹72.22 Cr ₹91.54 Cr ₹80.38 Cr ₹90.65 Cr ₹107.88 Cr ₹115.21 Cr ₹122.79 Cr ₹99.62 Cr
Purchases of Stock-in-Trade ₹29.08 Cr ₹32.99 Cr ₹38.82 Cr ₹39.23 Cr ₹30.62 Cr ₹34.94 Cr ₹39.14 Cr ₹36.23 Cr ₹27.17 Cr ₹30.62 Cr ₹25.74 Cr ₹32.13 Cr
Changes in Inventories ₹10.58 Cr -₹1.59 Cr ₹4.04 Cr -₹5.83 Cr -₹12.98 Cr -₹22.26 Cr -₹1.47 Cr ₹4.67 Cr ₹6.38 Cr -₹9.62 Cr -₹5.78 Cr -₹5.68 Cr
Employee Benefit Expense ₹100.98 Cr ₹98.81 Cr ₹95.34 Cr ₹98.5 Cr ₹99.94 Cr ₹90.72 Cr ₹87.3 Cr ₹90.78 Cr ₹82.87 Cr ₹87.34 Cr ₹90.02 Cr ₹90.32 Cr
Finance Costs ₹22.73 Cr ₹20.15 Cr ₹22.01 Cr ₹23.61 Cr ₹15.98 Cr ₹14 Cr ₹14.77 Cr ₹11.88 Cr ₹10.91 Cr ₹10.03 Cr ₹8.1 Cr ₹7.78 Cr
Depreciation & Amortisation ₹26.71 Cr ₹27.36 Cr ₹27.63 Cr ₹25.2 Cr ₹24.88 Cr ₹24.75 Cr ₹24.92 Cr ₹23.7 Cr ₹23.73 Cr ₹22.97 Cr ₹21.41 Cr ₹19.87 Cr
Other Expenses ₹147.21 Cr ₹163.21 Cr ₹164.51 Cr ₹158.03 Cr ₹153.99 Cr ₹157.9 Cr ₹138.31 Cr ₹127.53 Cr ₹163.83 Cr ₹160.21 Cr ₹168.2 Cr ₹143.58 Cr
Total Expenses ₹435.54 Cr ₹422.12 Cr ₹438.37 Cr ₹426.51 Cr ₹384.65 Cr ₹391.59 Cr ₹383.35 Cr ₹385.44 Cr ₹422.77 Cr ₹416.76 Cr ₹430.48 Cr ₹387.62 Cr
Profit Before Exceptional Items & Tax ₹23.94 Cr -₹14.44 Cr ₹10.29 Cr -₹28.4 Cr -₹30.9 Cr -₹14.35 Cr ₹17.38 Cr ₹19.51 Cr ₹26.77 Cr ₹35.22 Cr ₹44.03 Cr ₹35.67 Cr
Exceptional Items ₹3.68 Cr -₹6.01 Cr -₹53 Lakh ₹0 ₹0 ₹99 Lakh ₹0 ₹0 ₹19.73 Cr -₹8.2 Cr ₹0 ₹0
Profit Before Tax ₹27.62 Cr -₹20.45 Cr ₹9.76 Cr -₹28.4 Cr -₹30.9 Cr -₹13.36 Cr ₹17.38 Cr ₹19.51 Cr ₹46.5 Cr ₹27.02 Cr ₹44.03 Cr ₹35.67 Cr
Total Tax Expense ₹27 Lakh -₹45 Lakh -₹5.29 Cr -₹34 Lakh -₹4.66 Cr -₹3.13 Cr ₹4.59 Cr ₹4.56 Cr ₹8.94 Cr ₹7.01 Cr ₹10.89 Cr ₹9.73 Cr
Net Profit ₹27.35 Cr -₹20 Cr ₹15.05 Cr -₹28.06 Cr -₹26.24 Cr -₹10.23 Cr ₹12.79 Cr ₹14.95 Cr ₹37.56 Cr ₹20.01 Cr ₹33.14 Cr ₹25.94 Cr
Other Comprehensive Income ₹50 Lakh -₹15 Lakh ₹57 Lakh ₹41 Lakh -₹3.82 Cr -₹22 Lakh -₹23 Lakh -₹22 Lakh ₹71 Lakh -₹22 Lakh -₹22 Lakh -₹23 Lakh
Total Comprehensive Income ₹27.85 Cr -₹20.15 Cr ₹15.62 Cr -₹27.65 Cr -₹30.06 Cr -₹10.45 Cr ₹12.56 Cr ₹14.73 Cr ₹38.27 Cr ₹19.79 Cr ₹32.92 Cr ₹25.71 Cr
EBITDA (computed) ₹73.38 Cr ₹33.07 Cr ₹59.93 Cr ₹20.41 Cr ₹9.96 Cr ₹24.4 Cr ₹57.07 Cr ₹55.09 Cr ₹61.41 Cr ₹68.22 Cr ₹73.54 Cr ₹63.32 Cr
Basic EPS ₹2.96 ₹-2.17 ₹1.63 ₹-3.04 ₹-2.85 ₹-1.11 ₹1.39 ₹1.62 ₹4.08 ₹2.17 ₹3.60 ₹2.81
Diluted EPS ₹2.96 ₹-2.17 ₹1.63 ₹-3.04 ₹-2.84 ₹-1.11 ₹1.39 ₹1.62 ₹4.07 ₹2.17 ₹3.59 ₹2.81
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Indoco Pharmchem Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Indoco Pharmchem Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 58.86%, foreign institutional investors hold 0.94%, domestic institutional investors hold 18.15%, retail and other public shareholders hold 21.90% of Indoco Pharmchem Limited. The company had 32,276 shareholders on record.

Promoters: 58.86%DII (Domestic Institutional): 18.15%FII (Foreign Institutional): 0.94%Retail & Others: 21.90%
Mar 2026
QUARTER
58.86% Promoters
18.15% DII (Domestic Institutional)
0.94% FII (Foreign Institutional)
21.90% Retail & Others
Promoter holding - history
Now 58.86% · Mar 2026High 59.25% · Mar 2016Low 58.68% · Mar 2019
57%58%59%60%61%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 59.23%Mar 2016: 59.25%Jun 2016: 59.24%Sep 2016: 59.16%Dec 2016: 59.15%Mar 2017: 59.11%Jun 2017: 59.10%Sep 2017: 58.85%Dec 2017: 58.85%Mar 2018: 58.87%Jun 2018: 58.87%Sep 2018: 58.87%Dec 2018: 58.83%Mar 2019: 58.68%Jun 2019: 58.68%Sep 2019: 58.69%Dec 2019: 58.68%Mar 2020: 58.68%Jun 2020: 58.69%Sep 2020: 58.69%Dec 2020: 58.69%Mar 2021: 58.69%Jun 2021: 58.69%Sep 2021: 58.69%Dec 2021: 58.69%Mar 2022: 58.69%Jun 2022: 58.69%Sep 2022: 58.69%Dec 2022: 58.69%Mar 2023: 58.69%Jun 2023: 58.73%Sep 2023: 58.74%Dec 2023: 58.74%Mar 2024: 58.72%Jun 2024: 58.75%Sep 2024: 58.75%Dec 2024: 58.80%Mar 2025: 58.90%Jun 2025: 58.90%Sep 2025: 58.90%Dec 2025: 58.90%Mar 2026: 58.86%59.25%58.68%58.86%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters58.86%58.90%58.90%58.90%58.90%58.80%
Public41.00%41.01%41.01%41.01%41.01%41.17%
Employee Trusts0.14%0.09%0.09%0.09%0.09%0.03%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters58.86%58.90%58.72%58.69%58.69%58.69%58.68%58.68%58.87%59.11%59.25%
Public41.00%41.01%41.24%41.31%41.31%41.31%41.31%41.32%41.13%40.89%40.75%
Employee Trusts0.14%0.09%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Promoter change (YoY, %pts)-0.04+0.18+0.03+0.00+0.00+0.01+0.00-0.19-0.24-0.14-

Board & Governance of Indoco Pharmchem Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Indoco Pharmchem Limited has 8 directors - 4 independent and 2 executive. The board is chaired by SURESH GOVIND KARE.

DirectorPositionOn board sinceListed boards
SURESH GOVIND KARE Non-Executive - Non Independent Director · Chairperson 1963-07-02 1
ADITI M PANANDIKAR Executive Director · MD 2004-03-27 1
SUNDEEP VASANT BAMBOLKAR Executive Director · MD 2004-03-27 1
VASUDHA VASANT KAMAT Non-Executive - Independent Director 2020-03-27 1
ANAND MADHUSUDAN NADKARNI Non-Executive - Non Independent Director 2014-05-28 1
ABHIJIT YASHWANT GORE Non-Executive - Independent Director 2020-10-03 1
SATISH MADHAV SHENOY Non-Executive - Independent Director 2024-04-01 1
AJAY PRASAN MULGAOKAR Non-Executive - Independent Director 2024-04-01 1
Board Committees
CommitteeMembers
Audit Committee SATISH MADHAV SHENOY (Chairperson), AJAY PRASAN MULGAOKAR, VASUDHA VASANT KAMAT, ABHIJIT YASHWANT GORE, SUNDEEP VASANT BAMBOLKAR
Nomination and remuneration committee ABHIJIT YASHWANT GORE (Chairperson), AJAY PRASAN MULGAOKAR, ANAND MADHUSUDAN NADKARNI
Stakeholders Relationship Committee ABHIJIT YASHWANT GORE (Chairperson), ADITI M PANANDIKAR, SUNDEEP VASANT BAMBOLKAR
Risk Management Committee SATISH MADHAV SHENOY (Chairperson), AJAY PRASAN MULGAOKAR, ANAND MADHUSUDAN NADKARNI, ADITI M PANANDIKAR, SUNDEEP VASANT BAMBOLKAR
Corporate Social Responsibility Committee ADITI M PANANDIKAR (Chairperson), VASUDHA VASANT KAMAT, SUNDEEP VASANT BAMBOLKAR

Charges & Borrowings Indoco Pharmchem Limited

Indoco Pharmchem Limited does not have any charges (loans) registered with the Registrar of Companies.

Employees and EPFO Compliance at Indoco Pharmchem Limited

View historical data on people associated with Indoco Pharmchem Limited, including employment history and EPFO contributions.

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Indoco Pharmchem Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Indoco Pharmchem Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Indoco Pharmchem Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Indoco Pharmchem Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Indoco Pharmchem Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Indoco Pharmchem Limited

MSME Payment Delays by Indoco Pharmchem Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Indoco Pharmchem Limited

Subsidiaries & Group Companies of Indoco Pharmchem Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Indoco Pharmchem Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Indoco Pharmchem Limited

MCA Filings & Documents of Indoco Pharmchem Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Indoco Pharmchem Limited

Activity
08 Aug 2017
Indoco Pharmchem Limited last Annual general meeting of members was held on 08 Aug 2017 as per latest MCA records.
Activity
31 Mar 2017
Indoco Pharmchem Limited has filed its annual Financial statements for the year ended 31 Mar 2017 with Roc Mumbai.
Directors
26 Jun 2012
Sundeep Vasant Bambolkar was appointed as a Director on 26 Jun 2012 & has been associated with this company since 14 years 13 days.
Directors
26 Jun 2012
Aditi Milind Panandikar was appointed as a Director on 26 Jun 2012 & has been associated with this company since 14 years 13 days.
Directors
26 Jun 2012
Suresh Govind Kare was appointed as a Director on 26 Jun 2012 & has been associated with this company since 14 years 13 days.
Activity
26 Jun 2012
Indoco Pharmchem Limited was registered on 26 Jun 2012 with Roc Mumbai & aged 14 years 13 days as per MCA records.

Recent News on Indoco Pharmchem Limited

Frequently Asked Questions about Indoco Pharmchem Limited

Indoco Pharmchem Limited has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.

Indoco Pharmchem Limited is a struck-off public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 26 June 2012 and is registered under CIN U33112MH2012PLC232609. The company has been struck off by the Registrar of Companies and is no longer operational.

The current directors of Indoco Pharmchem Limited are:

The CIN (Corporate Identification Number) of Indoco Pharmchem Limited is U33112MH2012PLC232609. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

The primary industry of Indoco Pharmchem Limited is pharma. The company specifically operates in drug formulation and development. The company was active in this sector before being struck off.

The company has its registered office at Indoco House 166 Cst Road Santacruz East, Mumbai, Maharashtra, India – 400098.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available